News: Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

709.05INR
31 Jul 2015
Change (% chg)

Rs-2.00 (-0.28%)
Prev Close
Rs711.05
Open
Rs719.90
Day's High
Rs724.00
Day's Low
Rs706.00
Volume
2,031,688
Avg. Vol
1,665,502
52-wk High
Rs752.85
52-wk Low
Rs430.00

Search Stocks
Select another date:

Wed, Jun 17 2015

India's Cipla expects to double respiratory drug sales by 2020

MUMBAI - Indian generic drugmaker Cipla expects sales from its respiratory portfolio to more than double by 2020 and remains on track to launch its potentially lucrative inhaler in Britain, its chief executive said.

Interview - Cipla expects to double respiratory drug sales by 2020

MUMBAI - Generic drugmaker Cipla expects sales from its respiratory portfolio to more than double by 2020 and remains on track to launch its potentially lucrative inhaler in Britain, its chief executive said.

India's Cipla to sharpen focus on emerging markets in growth push

MUMBAI, June 17 - Cipla Ltd, India's fourth-largest drugmaker by sales, is planning to enter Latin America and Eastern Europe to tap into growing demand for generic drugs in emerging markets, Chief Executive Subhanu Saxena said.

India's Lupin, Cipla bid for UCB's US generic drugs portfolio - Bloomberg

MUMBAI, June 1 - Indian generic drugmakers Lupin Ltd and Cipla Ltd are among the companies bidding for top Belgian drugmaker UCB SA's U.S. generic drugs business, Bloomberg reported on Monday, citing unnamed people with knowledge of the matter.

Germany's Boehringer loses India patent on lung drug to Cipla

MUMBAI, March 10 - India has revoked a patent on German pharmaceutical company Boehringer Ingelheim's lung drug Spiriva and ruled in favour of domestic drugmaker Cipla Ltd , in the latest setback for a multinational drugmaker operating in India.

BRIEF-India's Cipla agrees to buy 60 pct stake in Jay Precision for $15 mln

* Says agrees to buy 60 percent stake in Jay Precision Pharmaceuticals Pvt Ltd for 960 million rupees ($15.44 million) in cash

India's Cipla Q3 net profit up 15.5 pct

MUMBAI, Feb 12 - Cipla Ltd, India's fourth-largest drugmaker by sales, on Thursday reported a 15.5 percent rise in its third-quarter profit, slightly lagging analysts' estimates.

Select another date:

Press Releases

Search Stocks